| Requirement for p53 and p21 to sustain G2 arrest after DNA damage F Bunz, A Dutriaux, C Lengauer, T Waldman, S Zhou, JP Brown, ... Science 282 (5393), 1497-1501, 1998 | 3604 | 1998 |
| p21 Is Necessary for the p53-mediated G1 Arrest in Human Cancer Cells T Waldman, KW Kinzler, B Vogelstein Cancer research 55 (22), 5187-5190, 1995 | 1651 | 1995 |
| Disruption of p53 in human cancer cells alters the responses to therapeutic agents F Bunz, PM Hwang, C Torrance, T Waldman, Y Zhang, L Dillehay, ... The Journal of clinical investigation 104 (3), 263-269, 1999 | 1309 | 1999 |
| Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 T Waldman, C Lengauer, KW Kinzler, B Vogelstein Nature 381 (6584), 713-716, 1996 | 947 | 1996 |
| Topological Control of p21WAF1/CIP1 Expression in Normal and Neoplastic Tissues WS El-Deiry, T Tokino, T Waldman, JD Oliner, VE Velculescu, M Burrell, ... Cancer research 55 (13), 2910-2919, 1995 | 807 | 1995 |
| Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors AM Mendes‐Pereira, SA Martin, R Brough, A McCarthy, JR Taylor, JS Kim, ... EMBO molecular medicine 1 (6‐7), 315-322, 2009 | 732 | 2009 |
| Genetic determinants of p53-induced apoptosis and growth arrest. K Polyak, T Waldman, TC He, KW Kinzler, B Vogelstein Genes & development 10 (15), 1945-1952, 1996 | 621 | 1996 |
| Mutational inactivation of STAG2 causes aneuploidy in human cancer DA Solomon, T Kim, LA Diaz-Martinez, J Fair, AG Elkahloun, BT Harris, ... Science 333 (6045), 1039-1043, 2011 | 548 | 2011 |
| Cell-cycle arrest versus cell death in cancer therapy T Waldman, Y Zhang, L Dillehay, J Yu, K Kinzler, B Vogelstein, J Williams Nature medicine 3 (9), 1034-1036, 1997 | 469 | 1997 |
| Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma R Hashizume, N Andor, Y Ihara, R Lerner, H Gan, X Chen, D Fang, ... Nature medicine 20 (12), 1394-1396, 2014 | 466 | 2014 |
| The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation AS Brohl, DA Solomon, W Chang, J Wang, Y Song, S Sindiri, R Patidar, ... PLoS genetics 10 (7), e1004475, 2014 | 420 | 2014 |
| Oncogenic mutations of PIK3CA in human cancers Y Samuels, T Waldman Phosphoinositide 3-kinase in Health and Disease: Volume 2, 21-41, 2011 | 345 | 2011 |
| Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts K Michaud, DA Solomon, E Oermann, JS Kim, WZ Zhong, MD Prados, ... Cancer research 70 (8), 3228-3238, 2010 | 338 | 2010 |
| The metastasis-associated gene S100A4 is a novel target of β-catenin/T-cell factor signaling in colon cancer U Stein, F Arlt, W Walther, J Smith, T Waldman, ED Harris, SD Mertins, ... Gastroenterology 131 (5), 1486-1500, 2006 | 263 | 2006 |
| Repair Defect in p21WAF1/CIP1 -/- Human Cancer Cells ER McDonald III, GS Wu, T Waldman, WS El-Deiry Cancer research 56 (10), 2250-2255, 1996 | 244 | 1996 |
| p53 tagged sites from human genomic DNA T Tokino, S Thiagalingam, WS Ei-deiry, T Waldman, KW Kinzler, ... Human molecular genetics 3 (9), 1537-1542, 1994 | 239 | 1994 |
| Frequent truncating mutations of STAG2 in bladder cancer DA Solomon, JS Kim, J Bondaruk, SF Shariat, ZF Wang, AG Elkahloun, ... Nature genetics 45 (12), 1428-1430, 2013 | 235 | 2013 |
| Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells HF Li, JS Kim, T Waldman Radiation oncology 4, 1-10, 2009 | 234 | 2009 |
| Oncogenic β-catenin is required for bone morphogenetic protein 4 expression in human cancer cells JS Kim, H Crooks, T Dracheva, TG Nishanian, B Singh, J Jen, T Waldman Cancer research 62 (10), 2744-2748, 2002 | 219 | 2002 |
| p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells L Cen, BL Carlson, MA Schroeder, JL Ostrem, GJ Kitange, AC Mladek, ... Neuro-oncology 14 (7), 870-881, 2012 | 204 | 2012 |
